drugset / Trial / NCT03144856
Apatinib as Second Line Therapy in Patients With Advanced Refractory Biliary Tract Cancers
NaSingle-groupOpen-labelTreatment
Summary
This study is designed to see whether Apatinib is effective in treating patients with advanced refractory biliary tract cancers.
Timeline
- Start
- 2017-02-22
- Primary completion
- 2019-03-01
- Completion
- 2019-03-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rivoceranib | Small molecule | 500 mg | Oral |